CABENUVA 200 MG / ML
CABENUVA · DIN 02497247 · VIIV HEALTHCARE ULC
Health Canada status: MARKETED
What is CABENUVA?
CABENUVA 200 MG / ML contains CABENUVA. It is listed in the Health Canada Drug Product Database under DIN 02497247, held by VIIV HEALTHCARE ULC. Health Canada currently lists it as marketed, status dated 21-Sep-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CABENUVA used for?
Treatment of HIV-1 in virologically stable/suppressed (HIV-1 RNA <50 copies/mL) patients ≥12 years and ≥35 kg. VOCABRIA used as oral lead-in or bridging; CABENUVA as complete long-acting regimen.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02497247 |
|---|---|
| Brand name | CABENUVA |
| Manufacturer | VIIV HEALTHCARE ULC |
| Strength | 200 MG / ML |
| Schedule | PRESCRIPTION |
| Health Canada status | MARKETED |
| Status date | 21-Sep-2020 |
How is it administered?
Oral lead-in (30mg/25mg) for ~28 days (optional). Initiation: 600mg/900mg IM. Continuation: 400mg/600mg IM monthly or 600mg/900mg IM every 2 months. Gluteal IM injection only.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
CABENUVA: Store at 2°C to 8°C. Do not freeze. VOCABRIA: Store at 15°C to 30°C.
How is it supplied?
VOCABRIA: 30 mg tablets. CABENUVA: 2 mL and 3 mL dosing kits containing cabotegravir and rilpivirine suspensions.
Contraindications
Hypersensitivity to cabotegravir or rilpivirine. Co-administration with strong inducers of UGT1A1/UGT1A9 (e.g., carbamazepine, rifampin, phenytoin), rifabutin, systemic dexamethasone, St John’s wort.
Warnings and precautions
Risk of virologic failure/resistance if doses missed. Depressive disorders, hepatotoxicity, post-injection reactions, and hypersensitivity reactions reported. Long-acting properties persist after stop.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.